A prospective study of 24 men found that 18F-Flotufolastat PSMA PET MRI detected recurrent prostate cancer in 25 percent of ...
A clinical case report documents an asymptomatic 73-year-old prostate cancer patient whose biochemical recurrence led to the ...
DASL-HiCaP Trial Shows Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer / DASL-HiCaP Trial, ...
What’s New On Radiotherapy of Prostate Cancer in 2026? / OncoDaily RT, prostate cancer, prostate cancer radiotherapy, ...
Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to ...
The 2026 ESMO annual meeting featured a prostate cancer proffered paper session and a discussant presentation by Dr. Nicholas van As discussing two abstracts “Perioperative apalutamide + ADT with ...
Men's Fitness on MSN
Your prostate at 40, 50, 60 and 70: what's normal, what's not and when to be concerned
What happens to your prostate as you get older? One expert explains what's normal at 40, 50, 60 and 70, common symptoms to ...
A Phoenix man with metastatic castration-sensitive prostate cancer shares how back pain led to a PSA test and how his family helped him cope. Prostate cancer grows slowly, and while 50% of men on ...
AI-driven technology reduces radiation therapy to one to five sessions Consistent, vigilant PSA testing leads to early diagnosis, treatment ART/SBRT continuously pinpoints tumor, spares healthy tissue ...
ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results